Search results
Merck Gambled With Keytruda In 2011 — How That Jump Is Still Paying Off Today
Investor's Business Daily· 2 years agoA gamble Merck made more than 10 years ago could pay off again for the pharmaceutical giant's stock...
'Extraordinary' study results offer new hope for advanced lung cancer patients being treated with...
USA TODAY via Yahoo News· 2 years agoPatients with advanced lung cancer had a better chance at survival when their treatment combined...
Advanced Lung Cancer and Immunotherapy
Verywell Health via Yahoo News· 8 months agoImmunotherapy is a newer class of treatment for lung and other cancers. It primes the body’s natural immune system to fight back against cancer....
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test
Investor's Business Daily· 2 months agoModerna stock surged Monday — nearing its first breakout in over a year — after launching a third...
In what could be a 'big shift' for cancer treatment, mRNA vaccine shows promise against melanoma
USA TODAY via Yahoo News· 1 year agoMessenger RNA vaccines aren't just for COVID anymore. The vaccine technology America learned about...
The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen — And Could Succeed
Investor's Business Daily· 2 years agoShares of MRTX stock rocketed Tuesday after Mirati Therapeutics unveiled early — but promising —...
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Reuters via Yahoo News· 1 year ago(Reuters) -Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic ...
Cancer vaccine being trialled by NHS may herald ‘dawn of a new age’ of treatments
The Independent via Yahoo News· 3 months agoA new mRNA cancer vaccine being trialled in the UK could herald the “dawn of a new age” of...
Mirati drug helps some patients whose lung cancer spread to the brain -study
Reuters via Yahoo News· 2 years agoMirati Therapeutics Inc's experimental drug that targets a specific genetic mutation helped about...
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
Motley Fool via Yahoo Finance· 4 months agoOn Dec. 14, Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) jointly reported some great news for...
